Skip to main content

Table 3 Treatment-related adverse events in patients treated with nivolumab

From: Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma

Event Any grade Grade 3 or 4
  Number of patients (%)
Fatigue / Malaise 5 (12%) 1 (2%)
Fever 4 (10%) 3 (7%)
Rash / Skin Toxicity 4 (10%) 2 (5%)
Hypothyroidism 3 (7%) 0
Diarrhea 2 (5%) 1 (2%)
Arthralgia 2 (5%) 0
Myalgia / Myositis 2 (5%) 0
Adrenal Insufficiency 2 (5%) 0
Peripheral Edema 2 (5%) 0
Heart Block (3rd degree) 1 (2%) 1 (2%)
Respiratory Failure 1 (2%) 1 (2%)
Headache 1 (2%) 1 (2%)
Aphasia 1 (2%) 0
Infusion Reaction 1 (2%) 0
Diabetes 1 (2%) 0
Uveitis 1 (2%) 0
Hypertension 1 (2%) 0
Hypophysitis 1 (2%) 0
Cough 1 (2%) 0
Lymphadenopathy 1 (2%) 0
Back Pain 1 (2%) 0